Natera, Inc. (NASDAQ:NTRA) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 58.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,335 shares of the medical research company's stock after selling 25,358 shares during the quarter. Teacher Retirement System of Texas' holdings in Natera were worth $2,593,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its holdings in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. M&T Bank Corp lifted its position in shares of Natera by 27.6% in the fourth quarter. M&T Bank Corp now owns 7,033 shares of the medical research company's stock valued at $1,113,000 after acquiring an additional 1,520 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Natera in the fourth quarter valued at $16,113,000. PNC Financial Services Group Inc. boosted its stake in shares of Natera by 6.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,951 shares of the medical research company's stock valued at $467,000 after acquiring an additional 186 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Natera by 14.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,231 shares of the medical research company's stock worth $4,786,000 after purchasing an additional 3,892 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 5,343 shares of the business's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $166.53, for a total transaction of $889,769.79. Following the transaction, the chief executive officer owned 173,728 shares in the company, valued at $28,930,923.84. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider owned 130,205 shares in the company, valued at approximately $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,272 shares of company stock valued at $8,345,368 in the last 90 days. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $2.93 during trading on Friday, reaching $160.43. 710,024 shares of the stock were exchanged, compared to its average volume of 1,422,191. The firm's 50-day moving average price is $161.05 and its 200 day moving average price is $158.44. The firm has a market cap of $21.91 billion, a price-to-earnings ratio of -109.14 and a beta of 1.73. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period in the previous year, the firm earned ($0.56) earnings per share. Natera's revenue for the quarter was up 36.5% on a year-over-year basis. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NTRA. Royal Bank Of Canada began coverage on shares of Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Piper Sandler raised their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.